Our Integrated Platform
In Silico → In Vitro → In Vivo Flywheel
An AI-powered discovery engine that predicts, validates, and optimizes small molecules for cell rejuvenation — each cycle improving on the last.
In Silico
Target Discovery
Proprietary AI models identify the molecular drivers of cellular exhaustion — mapping which proteins to modulate to restore function.
Compound Discovery
Screening vast molecular libraries against those targets to find small molecules with high selectivity and low off-target interactions.
In Vitro
Compound Validation
Rapid biological validation using human T cells, with standardized assays measuring polyfunctionality, exhaustion markers, and proliferative capacity.
In Vivo
Preclinical Validation
Testing in animal models to confirm that compound-enhanced T cells maintain their improved function in living systems.
Our preclinical program advances toward first-in-human trials in 2026.
Results
Examples of how dysfunctional T cells can be reprogrammed ex vivo and in vivo to increase their antiviral capacity against chronic viral infection.
Our lead compound achieved a 6.6x improvement in T cell polyfunctionality and 90.5% antitumor capacity against HER2+ solid tumor cells — validated independently at Baylor College of Medicine (Houston), IDCBIS (Bogotá), and CellRep laboratories. Improvements are achieved during CAR-T manufacturing only; compounds are washed out before cells reach the patient.
From cancer immunotherapy to cellular longevity
Some of Our Relevant papers
Examples of how dysfunctional T cells can be reprogrammed ex vivo and in vivo to increase their antiviral capacity against chronic viral infection.
This is a little glimpse of our science.
